Sandip Kapadia Net Worth

The estimated Net Worth of Sandip Kapadia is at least $2.92 Million dollars as of 29 March 2024. Mr. Kapadia owns over 15,000 units of Intercept Pharmaceuticals Inc stock worth over $285,000 and over the last 8 years he sold ICPT stock worth over $312,225. In addition, he makes $2,326,640 as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Kapadia ICPT stock SEC Form 4 insiders trading

Sandip has made over 8 trades of the Intercept Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ICPT stock worth $285,000 on 29 March 2024.

The largest trade he's ever made was exercising 30,000 units of Intercept Pharmaceuticals Inc stock on 29 March 2023 worth over $570,000. On average, Sandip trades about 1,898 units every 77 days since 2016. As of 29 March 2024 he still owns at least 15,000 units of Intercept Pharmaceuticals Inc stock.

You can see the complete history of Mr. Kapadia stock trades at the bottom of the page.

Sandip Kapadia biography

Sandip S. Kapadia serves as Chief Financial Officer, Treasurer of the Company. Mr. Kapadia has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and abroad. Prior to joining the Company, Mr. Kapadia held finance leadership positions over 19 years at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, including most recently Chief Financial Officer of North America at Novartis’s generic division, Sandoz. Mr. Kapadia has been a director of Therachon AG since January 2019. Mr. Kapadia earned his bachelor’s degree in business administration and accounting from Montclair State University, an M.B.A from Rutgers Graduate School of Management and is a certified public accountant.

What is the salary of Sandip Kapadia?

As the Chief Financial Officer and Treasurer of Intercept Pharmaceuticals Inc, the total compensation of Sandip Kapadia at Intercept Pharmaceuticals Inc is $2,326,640. There are 4 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.

How old is Sandip Kapadia?

Sandip Kapadia is 50, he's been the Chief Financial Officer and Treasurer of Intercept Pharmaceuticals Inc since 2016. There are 20 older and 3 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.

What's Sandip Kapadia's mailing address?

Sandip's mailing address filed with the SEC is ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 19103.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Complete history of Mr. Kapadia stock trades at Intercept Pharmaceuticals Inc, Passage Bio Inc, and Harmony Biosciences

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Pruzanski,
  President, Chief Executive Officer, Director
• Jerome Durso,
  Chief Operating Officer
• Ryan Sullivan,
  General Counsel, Secretary
• Richard Kim,
  President, U.S. Commercial & Strategic Marketing
• Sandip Kapadia,
  Chief Financial Officer, Treasurer
• Gail Cawkwell,
  Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
• Lisa Bright,
  President, International
• David Ford,
  Chief Human Resource Officer
• Dr. Mark Pruzanski M.D.,
  Founder, Advisor & Director
• Jerome B. Durso,
  Pres, CEO & Director
• Paolo Fundaro,
  Independent Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Daniel Welch,
  Independent Director
• Daniel Bradbury,
  Independent Director
• Luca Benatti,
  Independent Director
• Nancy Miller-Rich,
  Independent Director
• Keith Gottesdiener,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Jason Campagna,
  Chief Medical Officer
• Christian Weyer,
  Executive Vice President - Research & Development
• Linda M. Richardson,
  Exec. VP & Chief Commercial Officer
• Jared M. Freedberg J.D.,
  Gen. Counsel
• Lisa M. DeFrancesco,
  Sr. VP of Corp. Affairs & Investor Relations
• Rocco Venezia,
  Chief Accounting Officer & Treasurer
• Bryan Ball,
  Chief Quality Officer & Sr. VP of Operations
• Andrew Saik,
  Chief Financial Officer
• Barbara Gayle Duncan,
  Chief Financial Officer
• Rachel Mc Minn,
  Chief Strategy Officer
• David Shapiro,
  Chief Medical Officer
• Linda M Richardson,
  EVP & Chief Commercial Officer
• S.P.A. Genextra,
  
• M Michelle Berrey,
  President, R&D and CMO
• Daniel Paul Regan,
  Chief Commerical Officer
• Jonathan Silverstein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Lorenzo Tallarigo,
  Director
• Klaus R Dr Veitinger,
  Director
• Sanj K Patel,
  Director
• Luciano Adorini,
  Chief Scientific Officer
• Nicole Williams,
  Director
• Francesco Micheli,
  
• Bryan Ball,
  Chief Qual. Officer & SVP Ops.
• Rocco Venezia,
  Chief Accounting Officer
• Dagmar Rosa Bjorkeson,
  Director
• Lisa De Francesco,
  SVP, IR & Corp. Affairs
• Jared Freedberg,
  General Counsel